Introduction {#s1}
============

Gout is the most common inflammatory joint disease[@R1] with an impact on morbidity[@R5] and premature mortality.[@R8] The disease is heritable, as suggested by familial clustering of the disease;[@R11] however, the existence of many known risk factors, such as male gender, increasing age,[@R21] [@R22] obesity,[@R23] chronic renal impairment,[@R24] hypertension,[@R25] [@R26] long-term use of diuretics[@R27] and certain diets with high purine[@R28] and alcohol,[@R29] also supports a strong environmental contribution. Currently, the balance between genetic and environmental contributions is still unclear.

High heritability of hyperuricaemia,[@R30] the main driver of urate crystal deposition and the development of gout, has led to efforts to identify susceptibility genes. A large familial segregation study has demonstrated significant heritability for hyperuricaemia[@R30] and specific genetic associations, particularly genes involved in renal urate clearance, have been identified that mechanistically might explain genetic susceptibility to hyperuricaemia.[@R31] Despite the strong evidence supporting a genetic contribution to hyperuricaemia, studies concerning the relative contributions of genetic and environmental factors to gout are rare. A complex segregation analysis conducted in aborigines in Taiwan showed a substantial genetic component for gout,[@R35] but a recent classic twin study, with 514 all-male twin pairs in the US, paradoxically found significant heritability for hyperuricaemia but not for clinical gout.[@R36] Additionally, efforts largely failed to identify susceptibility genes to gout beyond genes controlling serum urate concentration, thus questioning the role of genetic factors in gout.[@R34]

Therefore, we undertook the first nationwide population-based study to estimate the degree of familial aggregation of gout and the extent to which heritability and a common familial environment might each account for familial aggregation. We studied this in Taiwan because, first, Taiwan has one of the highest reported estimates of gout prevalence worldwide[@R37] and, second, there is an established nationwide health insurance database containing sufficient demographic, family history and medical data on the entire Taiwanese population to allow us to address these questions.

Methods {#s2}
=======

The study was approved by the Institutional Review Board of Chang Gung Memorial Hospital (approval number 101-2178C).

Source of data {#s2a}
--------------

The primary data source came from the National Health Insurance Research Database (NHIRD), which contains registration information and original claims data on all beneficiaries of NHI in Taiwan since its establishment in 1995. All entries for an individual are linked by a unique personal identifier assigned to each Taiwanese resident, which allows accurate linkage of records from the registration files and from the original claims data. Before release for research, personal identifiers are deidentified to ensure confidentiality.

The registry of beneficiaries, one of the registration files, contains details of demographics, residence, kinship relationships, occupation categories, insurance status and insurance amount of all beneficiaries of NHI. Claims data on all outpatient visits, inpatient care and pharmacy dispensing were recorded in specific datasets with information, such as dates of events, medical diagnoses, medical expenditure and details of prescriptions, operations, examinations and procedures.

Study population and classification {#s2b}
-----------------------------------

The study population consisted of all NHI beneficiaries (11 360 576 men; 11 283 172 women) in 2004, representing 99.8% of the total population of Taiwan at the end of 2004.[@R38] Enrolled individuals were classified according to the affection status of gout of their first-degree and second-degree relatives who were registered in the NHI before 2004.

Identification of cases with gout {#s2c}
---------------------------------

The primary case definition of gout was having a physician-recorded diagnosis of gout (International Classification of Diseases, Ninth Revision \[ICD-9\] code: 274.x) together with at least one prescription containing gout-specific medications (colchicine, benzbromarone, allopurinol, probenecid, sulfinpyrazone) at either an outpatient or emergency visit during 2000--2004. An alternative definition, used for sensitivity analysis, was having two outpatient or emergency visits with a physician-recorded diagnosis of gout during 2000--2004. An identical case definition of gout was used for all individuals and their relatives.

Identification of first-degree and second-degree relatives and family ascertainment {#s2d}
-----------------------------------------------------------------------------------

The registry of beneficiaries specifies relationships between the insured person who pays the fee, and his/her dependents, allowing parent-offspring relationships and spouses to be identified directly. Among 28 402 865 individuals registered with the NHI during 1996--2010, 21 009 551 pairs of parent-offspring relationships were identified. Full siblings were identified as individuals who shared the same parents. Twins were full siblings who have the same date of birth (±1 day). Second-degree relatives were ascertained based on the aforementioned relationships. These links allowed the identification of 4 191 274 families spanning 2--5 generations.

Demographics and socioeconomic information {#s2e}
------------------------------------------

We also incorporated socioeconomic factors, including residence, occupations and income levels, to reflect population stratification with the aboriginals (with significantly higher prevalence of gout[@R39]) and Han people in Taiwan. For details of these factors, please refer to the online [supplementary materials](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2013-204067/-/DC1).

Statistical analysis {#s2f}
--------------------

The prevalence of gout was calculated for the general population and for individuals who had an affected spouse and/or affected relatives. Any individual fulfilling the case definitions of gout was defined as a prevalent case. For prevalence of gout in individuals with affected first-degree and second-degree relatives, age and sex were taken into account and age-standardised and sex-standardised prevalence (95% CI) was determined. The standard population used was the general population of Taiwan in 2004.

The degree of familial aggregation of gout was estimated using the relative risk (RR), which was calculated as the adjusted prevalence ratio between individuals with affected relatives and the entire population of Taiwan in 2004[@R40] The marginal Cox proportional hazard model with an equal follow-up time for all subjects with robust sandwich estimate,[@R41] [@R42] adjusted for age, place of residence, income, occupation and family size, was used to optimise the estimate of the RR. Because case clustering within a family may occur, the robust sandwich estimate was used when calculating confidence bounds.[@R41] The RR was estimated for individuals with different family relatives affected with gout, including first-degree and second-degree relatives affected, and for the number of affected first-degree relatives (father, mother, son, daughter, brother, sister).

We used the standard ACE model to examine the influences of additive genetic (A), common environmental factors shared by family members (C) and non-shared environmental factors (E) accounting for variance in a phenotype (P). This model can be expressed as:

where *σ*~p~^2^=total phenotypic variance; *σ*~c~^2^=common environmental variance; *σ*~c~^2^=common environmental variance and *σ*~E~^2^=non-shared environmental variance.

The heritability was defined as the proportion of phenotypic variance that is attributable to genetic factors and can be expressed as and the familial transmission was expressed as , which is the sum of heritability and common environmental variances.

We used the polygenic liability model to calculate both measures.[@R43] For details of this model, please see the online [supplementary material](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2013-204067/-/DC1). We used the sibling RR, spouse RR and the prevalence of gout in the general population (p) to calculate the familial transmission and the heritability, which were expressed as

where ; ; ; p=prevalence of gout in the normal population); a~R~: the additive genetic relationship between the relatives, for full sibling, a~R~=0.5; i=z/p; z, the height of the standard normal curve pertaining to gout prevalence, and Φ, standard normal cumulative distribution function.[@R46]

Therefore, the common environmental component was the difference between familial transmission and heritability. Since the epidemiologic and clinical features of gout are sexually dimorphic, and hence, equal genetic variances in both sexes may not hold true,[@R47] we estimated sex-specific familial transmission and heritability using respective sex-specific populations.

All analyses were performed for primary and alternative case definitions of gout. A 2-sided p value 0.05 was considered statistically significant. All analyses were performed using SAS V.9.3 (SAS institute, Cary, North Carolina, USA).

Results {#s3}
=======

Gout prevalence in individuals with affected family members versus the general population {#s3a}
-----------------------------------------------------------------------------------------

We identified 802 765 men and 242 294 women with gout in 2004 giving a crude prevalence of gout of 4.62% (95% CI 4.61% to 4.63%) (see online supplementary table S1). Men had a significantly higher prevalence (7.07%, 95% CI 7.05% to 7.08%) than women (2.15%, 95% CI 2.14% to 2.16%). We identified 1 663 904 individuals with at least one affected first-degree relative, and 604 468 individuals with at least one affected second-degree relative. The standardised prevalence of gout in individuals with affected first-degree and second-degree relatives were 13.37% (95% CI 13.35% to 13.39%) and 10.05% (95% CI 10.03% to 10.06%) in men, and 4.16% (95% CI 4.15% to 4.18%) and 3.01% (95% CI 3.00% to 3.02%) in women, respectively. [Figure 1](#ANNRHEUMDIS2013204067F1){ref-type="fig"}a and 1b show age-specific and sex-specific prevalence of gout in men and women which, at all ages, is higher in individuals with affected first-degree relatives than in those with second-degree relatives and the general population.

![Age-specific prevalence of gout in men (A) and women (B) according to the affection status of relatives (red, individuals with affected first-degree relatives; green, individuals with affected second-degree relatives; blue, the general population).](annrheumdis-2013-204067f01){#ANNRHEUMDIS2013204067F1}

Family exposure and risk of gout {#s3b}
--------------------------------

The risk of gout was significantly higher in individuals with affected first-degree relatives than in the general population, the RRs being 1.91 (95% CI 1.90 to 1.93) in men and 1.97 (95% CI 1.94 to 1.99) in women (see online supplementary table S2). Individuals with affected second-degree relatives also had an increased risk of gout, albeit significantly lower than those with affected first-degree relatives, with RRs of 1.27 (95% CI 1.23 to 1.31) in men and 1.40 (95% CI 1.35 to 1.46) in women. [Figure 2](#ANNRHEUMDIS2013204067F2){ref-type="fig"} shows that individuals with an affected twin had the highest risk, followed by individuals with an affected sibling, then individuals with an affected offspring and, finally, individuals with an affected parent. Same-sex twins had the highest RR, being higher in female-female twin pairs than male-male twin pairs. The RRs for gout in individuals with any category of affected second-degree relative ([table 1](#ANNRHEUMDIS2013204067TB1){ref-type="table"}) were lower than RRs in those with affected first-degree relatives ([figure 2](#ANNRHEUMDIS2013204067F2){ref-type="fig"}). The RRs also increased with the number of affected first-degree relatives. Compared with the general population, individuals with one, two or three or more categories of affected first-degree relatives had RRs (95% CIs) of 1.87 (1.86 to 1.89), 3.22 (3.15 to 3.29) and 4.96 (4.64 to 5.30), respectively. This trend was more prominent in women ([figure 3](#ANNRHEUMDIS2013204067F3){ref-type="fig"}).

###### 

Relative risk of gout among individuals with affected second-degree relatives in comparison with the general population in Taiwan in 2004

  Affected second-degree relatives   Men at risk   Women at risk          
  ---------------------------------- ------------- --------------- ------ --------------
  Grandparent                                                             
   Grandfather                       1.18          1.12 to 1.25    1.29   1.10 to 1.51
   Grandmother                       1.31          1.25 to 1.37    1.45   1.24 to 1.68
  Grandchild                                                              
   Grandson                          1.25          1.20 to 1.31    1.45   1.39 to 1.52
   Granddaughter                     1.39          1.21 to 1.59    1.54   1.33 to 1.78
  Uncle or aunt                                                           
   Uncle                             1.32          1.24 to 1.40    1.19   0.96 to 1.45
   Aunt                              1.21          0.98 to 1.48    0.91   0.41 to 2.03
  Nephew or niece                                                         
   Nephew                            1.42          1.34 to 1.51    1.16   0.95 to 1.41
   Niece                             1.42          1.16 to 1.74    0.90   0.41 to 2.00

![Relative risks (95% CI) of gout among (A) men and (B) women with affected first-degree relatives (square, male; circle, female) in comparison with the general population in Taiwan in 2004.](annrheumdis-2013-204067f02){#ANNRHEUMDIS2013204067F2}

![The 'dose-response' relationship between the numbers of affected first-degree relatives and relative risk of gout (blue: one; red: two; green: three first-degree relatives).](annrheumdis-2013-204067f03){#ANNRHEUMDIS2013204067F3}

Familial aggregation of gout was evident in individuals with affected biological relatives, and also in those with affected spouses. The RRs were 1.66 (1.65--1.68) in men with an affected wife and 1.65 (95% CI 1.64 to 1.67) in women with an affected husband.

Relative contributions of genetic, common and non-shared environmental factors {#s3c}
------------------------------------------------------------------------------

To separate the influences of genes and environment, we calculated heritability and familial transmission. In men, heritability was 35.1% (95% CI 34.1% to 36.0%) and familial transmission was 63.2% (95% CI 61.8% to 64.7%); whereas in women, they were 17.0% (95% CI 15.0% to 19.0%) and 35.5% (95% CI 33.1% to 37.8%), respectively. [Figure 4](#ANNRHEUMDIS2013204067F4){ref-type="fig"} shows the relative contributions of genetic (heritability), common environmental and non-shared environmental components to the phenotypic variances of gout.

![Relative contributions of heritability (blue), common environmental (red) and specific environmental factors (green) to phenotypic variation of gout.](annrheumdis-2013-204067f04){#ANNRHEUMDIS2013204067F4}

Sensitivity analysis {#s3d}
--------------------

We also used alternative case definition of gout to do sensitivity analysis. The results were very similar to our primary analysis (please see online [supplementary table](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2013-204067/-/DC1) S3, figures S1 and S2).

Discussion {#s4}
==========

This nationwide population study has confirmed familial aggregation of gout by demonstrating a greater prevalence and RR of gout for individuals with affected family members compared to the general population. The risk of gout is increased more by having affected first-degree relatives than having affected second-degree relatives, and appears 'dose-dependent' in that the risk increases with the number of affected relatives. These results confirm the long-held belief that gout clusters within families and supports an important contribution of common familial factors in predisposing to the development of gout.

However, biological relatives tend to share similar environmental and lifestyle risk factors in addition to genes; both contribute to familial aggregation. Therefore, we examined the risk associated with having a spouse who has gout on the assumption that any increased risk from this predominantly reflects predisposition from environmental and lifestyle factors common to family members. We found that the relative contributions differ between men and women; however, overall it appears that genetic factors play a smaller, but still substantial, role than environmental factors in the aetiology of gout. Our findings are consistent with the relative paucity of gout susceptibility genes identified by genome-wide association studies in comparison with greater numbers of genes associated with risk of hyperuricaemia, which has a greater heritability.[@R31]

Consistent with previous studies, our findings provide strong evidence to support the existence of familial aggregation of gout.[@R11] However, current evidence concerning the relative contributions of genetic and environmental exposures for gout susceptibility is limited. A complex segregation study conducted in the aborigines of Taiwan supported the existence of a substantial genetic predisposition to gout; however, no heritability estimate was reported.[@R35] By contrast, one recent study of 253 monozygotic and 261 dizygotic North American male twin pairs found a significant heritability for hyperuricaemia (49.6%) but, surprisingly, given that chronic hyperuricaemia is the key mechanism for urate crystal formation, no heritability (0%; 95% CI 0% to 61.8%) for gout.[@R36] Nevertheless, our whole population study provided several lines of evidence to support the existence of genetic predisposition to gout. First, our data on twin pairs showed significantly different risk profiles in same-sex twins compared to opposite-sex twins. Although lack of information on zygosity prevented the calculation of heritability based on twin data, the higher RR shared by same-sex (partly monozygotic) twins compared to opposite-sex (exclusively dizygotic) twins supports a genetic contribution. Second, using the spouse as an indicator of shared environmental risk, we estimated a heritability of 35.1% in men and 17.0% in women. Therefore, although not the sole explanation for familial aggregation, genetic factors in addition to environmental influences, do contribute to the development of gout.

It has long been observed that men are significantly more likely to have gout than women.[@R48] [@R49] Additionally, onset of gout is later in women.[@R50] The cause of this sexual dimorphism is not clear. One explanation is the uricosuric effect of oestrogen which results in lower serum urate levels in premenopausal women.[@R51] Therefore, prevalence of gout is generally low in premenopausal women and increases dramatically after menopause.[@R52] Different exposure to environmental risk factors may also contribute to the sex difference. For instance, dietary calorie intake and alcohol consumption are lower in women than men in Taiwan according to a national nutrition survey.[@R53] [@R54] Our study shows that familial transmission and heritability are both significantly higher in men. These findings suggest that genetic and common environmental factors are the main predisposing factors to gout in men, but not in women. Therefore, the sex difference can be partly attributed to different contributions from family factors. Further study is needed to confirm this finding.

There are several limitations to the study. First, it was confined to Taiwan, so results may not be generalisable to other settings. Second, the NHIRD is primarily a health insurance database that contains limited information on criteria for clinical diagnosis. We did not have data on potential confounding factors, therefore, we cannot test the interactions between family history and other confounders and their independent contributions to the risk of gout. Further, our analysis of relative genetic and environmental contributions was based on the multifactorial liability model, and our results are subject to assumptions, so should be interpreted with caution. However, the published data on other disease, such as schizophrenia[@R46] support the validity of this model. Finally, we cannot account for the effects of assortative mating whereby spouses are more similar for a phenotype than they would be if mating occurred at random in the population. If this assortment is not negligible, a biased estimation of relative genetic and environmental contributions may occur.[@R55]

Our main strengths include the use of data from the entire population of approximately 23 million individuals, and systematic methods to identify and ascertain first-degree and second-degree relatives, which allow very precise estimation of prevalence and RRs of gout with minimal selection bias. The virtually complete identification of gout cases, and the use of consistent case definitions for individuals at risk and their relatives, ensured the absence of information bias. Furthermore, we used prospectively recorded data for diagnosis, for construction of family relationships and for ascertaining socioeconomic information, thus minimising recall bias and other errors associated with self-reporting.

The present study provides quantitative estimates of familial RR and heritability for gout in an entire population of Taiwan. Our results confirm the clinical belief that gout clusters within families, and that genetic and environmental components contribute to its aetiology. Studies of familial risk in other populations are required to determine the generalisability of these findings to other populations.

Supplementary Material
======================
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